Title: 
Official Title: To amend title XI of the Social Security Act to expand and clarify the
            exclusion for orphan drugs under the Drug Price Negotiation Program.
Number of Sections: 2
Source: versions - Introduced in Senate
Media Type: text/xml

================================================================================

Section 1:
1.
            Short title
 This Act may be cited as the Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act.

Section 2:
2.
            Expanding and clarifying the exclusion for orphan drugs under the Drug Price
                Negotiation Program
 Section 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—
            
                (1)
 in paragraph (1), by adding at the end the following new subparagraph:   (C) Treatment of former orphan drugs In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).
                    
                    ; and
                
            
            
                (2)
 in paragraph (3)(A)—  (A) by striking only one rare disease or condition and inserting one or more rare diseases or conditions; and
                
                
                    (B)
 by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act).


================================================================================

Raw Text:
119 S1862 IS: Optimizing Research Progress Hope And New Cures Act
U.S. Senate
2025-05-22
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



        II
        119th CONGRESS
        1st Session
        S. 1862
        IN THE SENATE OF THE UNITED STATES
        
            May 22, 2025
            Mr. Barrasso (for himself and Mr. Heinrich) introduced the following bill; which
                was read twice and referred to the Committee
                    on Finance
        
        A BILL
        To amend title XI of the Social Security Act to expand and clarify the
            exclusion for orphan drugs under the Drug Price Negotiation Program.
    
    
        
            1.
            Short title
 This Act may be cited as the Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act.
        
        
            2.
            Expanding and clarifying the exclusion for orphan drugs under the Drug Price
                Negotiation Program
 Section 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—
            
                (1)
 in paragraph (1), by adding at the end the following new subparagraph:   (C) Treatment of former orphan drugs In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).
                    
                    ; and
                
            
            
                (2)
 in paragraph (3)(A)—  (A) by striking only one rare disease or condition and inserting one or more rare diseases or conditions; and
                
                
                    (B)
 by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act).